Stem Cell Sciences signs licence deal with Deltagen
Edinburgh-based stem cell research company, Stem Cell Sciences (SCS) has signed a major licensing agreement with US-based provider of drug discovery tools Deltagen, for use of its patented IRES technology.
Edinburgh-based stem cell research company, Stem Cell Sciences (SCS) has signed a major licensing agreement with US-based provider of drug discovery tools Deltagen, for use of its patented IRES technology.
IRES (Internal Ribosome Entry Sites) technology is a gene expression system used in cell-based drug screening and animal models of human diseases.
Deltagen will pay an up-front licence fee of US$1.2m as well as royalties based on revenues generated. As part of the deal, Stem Cell Sciences will also receive from Deltagen selected genetically-engineered mice.
The deal follows the recent granting of expanded claims for a key patent to SCS in relation to Stem Cell Selection in the US.